Posted inCardiagtech

Chromoblastomycosis Diagnosis: A Comprehensive Guide for Healthcare Professionals

No Comments

Introduction

Chromoblastomycosis is a long-term fungal infection affecting the skin and tissues beneath the skin, caused by a group of fungi known as dematiaceous fungi, which are characterized by their dark pigment. Predominantly found in tropical and subtropical regions, this neglected tropical disease arises when these fungi penetrate the skin, often through minor injuries encountered in environments rich in plant matter and soil. The infection’s hallmark is its slow progression, typically manifesting as raised, wart-like growths or plaques that resemble cauliflower in appearance and may eventually develop ulcers. Accurate and timely Chromoblastomycosis Diagnosis is crucial due to the infection’s potential for significant complications, including persistent skin thickening, secondary infections, and functional impairment. Distinguishing chromoblastomycosis from other conditions is essential for effective management. Treatment approaches vary depending on the severity, ranging from surgical removal for milder cases to prolonged courses of antifungal medications for more extensive infections. Long-term follow-up is vital to monitor treatment effectiveness and prevent recurrence. This article aims to provide an in-depth review of chromoblastomycosis, with a particular focus on chromoblastomycosis diagnosis, covering its epidemiology, causative agents, disease mechanisms, clinical presentation, and management strategies, to equip healthcare professionals with the necessary knowledge to enhance patient outcomes in this challenging condition.

Etiology of Chromoblastomycosis

Chromoblastomycosis is a mycotic infection caused by several species of dematiaceous fungi. These fungi, identifiable by their melanin or melanin-like pigment in their cell walls, are commonly found in soil and decaying plant material. While numerous species can cause chromoblastomycosis, the most frequently implicated genera include Fonsecaea and Cladophialophora. Specifically, Fonsecaea pedrosoi and Cladophialophora carrionii are the most commonly isolated species worldwide. Other genera and species less frequently associated with chromoblastomycosis include Exophiala, Phialophora, and Rhinocladiella.

Key etiological agents include:

  • Fonsecaea spp.: Notably F. pedrosoi, along with F. monophora, F. nubica, F. pugnacius, F. brasiliensis, and F. erecta.
  • Cladophialophora spp.: Predominantly C. carrionii and C. yegresii.
  • Exophiala spp.: Including E. dermatitidis (formerly Wangiella dermatitidis), E. spinifera, E. jeanselmei, and E. alcalophila.
  • Phialophora spp.: Such as P. verrucosa, P. americana, P. chinensis, and P. macrospora.
  • Rhinocladiella spp.: Including R. similis, R. mackenziei, and R. aquaspersa.

These fungi exist in nature as saprophytes, residing in environments like wood, soil, and various plant substrates. Infection typically occurs through traumatic inoculation, where fungal elements, such as conidia or mycelia, are introduced into the skin via cuts, punctures, or abrasions, often during agricultural or outdoor activities. Once in the tissue, these fungi transform into distinctive sclerotic bodies, a hallmark of chromoblastomycosis, and initiate a chronic granulomatous inflammatory response.

Epidemiology of Chromoblastomycosis

Chromoblastomycosis is predominantly a disease of tropical and subtropical climates, aligning with the geographical distribution of the causative dematiaceous fungi. It is considered a neglected tropical disease, with a significant impact on public health in endemic regions, particularly in rural agricultural communities. Studies from South America and the Caribbean indicate a strong male predominance, with over 80% of cases occurring in men, and a mean age of diagnosis around 56 years. This demographic bias is largely attributed to occupational exposure, as adult males are more likely to be engaged in agricultural work and outdoor activities that increase the risk of skin trauma and fungal inoculation. The lower limbs are the most frequently affected site, accounting for approximately 60% of lesions, likely due to increased exposure to soil and vegetation during agricultural work.

Common presenting symptoms include itching and pain associated with the lesions. The lesions themselves often present in verrucous or tumorous forms at the time of diagnosis, reflecting the chronic and progressive nature of the infection. While chromoblastomycosis primarily affects individuals with normal immune function, certain comorbidities, such as post-kidney transplant status, have been noted as risk factors, although these are less common than occupational exposure. Leprosy has also been reported as a concomitant infection in some cases.

The precise incidence of chromoblastomycosis remains challenging to ascertain due to underreporting and the absence of systematic surveillance in many endemic countries. It is generally underdiagnosed and underestimated, particularly in regions where it is not a notifiable disease. However, it is recognized as a significant health issue in several regions across South America, Africa, and Asia, with higher reported rates in countries like Costa Rica, Dominican Republic, Venezuela, French Guyana, Comoros, Madagascar, and Gabon. In regions like the United States and even parts of Asia like India, chromoblastomycosis is considered rare, often seen in travelers from endemic areas or immigrants. Despite its relatively low global prevalence compared to other infectious diseases, chromoblastomycosis poses a significant burden in endemic areas, leading to chronic morbidity and reduced quality of life, particularly among agricultural workers.

Pathophysiology of Chromoblastomycosis

The pathophysiology of chromoblastomycosis is characterized by a sequence of events initiated by the traumatic introduction of dematiaceous fungi into the skin. Following inoculation, the fungi elicit a chronic granulomatous and fibrotic reaction in the cutaneous and subcutaneous tissues. This process involves a complex interplay between the fungal pathogen and the host immune response.

Upon entering the skin, typically through a puncture wound, the fungal elements encounter host immune cells. Instead of being effectively eradicated, the dematiaceous fungi undergo a transformation into sclerotic bodies within phagocytic cells. These sclerotic bodies, also known as muriform bodies or medlar bodies, are distinctive, thick-walled, pigmented cells that are pathognomonic for chromoblastomycosis. Their unique morphology and dark pigmentation are key features in chromoblastomycosis diagnosis.

The host immune response in chromoblastomycosis is predominantly a T-helper cell type 2 (Th2) response, which is associated with chronic inflammation and fibrosis rather than effective fungal clearance. This Th2-biased response contributes to the formation of granulomas and microabscesses in the dermis and subcutaneous tissue. Sclerotic bodies become embedded within these granulomatous lesions, further perpetuating the inflammatory cycle. Clinically, the extrusion of sclerotic bodies through the epidermis is observed as characteristic black dots on the skin surface, often described as “cayenne pepper spots,” which are valuable diagnostic clues.

The pathogenesis of chromoblastomycosis is also influenced by fungal virulence factors and the host’s immune competence. Dematiaceous fungi possess several mechanisms that contribute to their persistence and pathogenicity in host tissues. Melanin, the pigment responsible for their dark color, plays a crucial role in protecting the fungi from oxidative stress and antifungal agents, and may interfere with phagocytic killing. Fungal enzymes, such as proteases, phospholipases, and catalases, may also contribute to tissue invasion and modulation of the host immune response.

The immune response to chromoblastomycosis is complex and involves both innate and adaptive immunity. While neutrophils and macrophages are recruited to the site of infection, their ability to eliminate intracellular fungi is limited, partly due to the protective effects of melanin. Dysfunction of Toll-like receptors (TLRs) on host cells may also impair the initiation of an effective antifungal immune response. Furthermore, chromoblastomycosis fungi can modulate the host’s cytokine profile, suppressing Th1 responses, which are crucial for cell-mediated immunity against intracellular pathogens, and promoting Th2 and Th17 responses, which contribute to chronic inflammation and fibrosis. Humoral immunity appears to play a less significant role in chromoblastomycosis. Genetic factors, such as mutations in CARD9 and specific HLA haplotypes, have been associated with increased susceptibility to chromoblastomycosis, suggesting a role for host genetic background in determining disease outcome.

Histopathology in Chromoblastomycosis Diagnosis

Histopathology plays a pivotal role in the definitive chromoblastomycosis diagnosis. A skin biopsy is essential for microscopic examination, revealing characteristic features that confirm the infection. The key histopathological findings include:

  • Pseudoepitheliomatous hyperplasia: This is a prominent epidermal reaction, characterized by an abnormal thickening of the epidermis that can mimic squamous cell carcinoma.
  • Irregular acanthosis and hyperkeratosis: The epidermis shows uneven thickening (acanthosis) and increased stratum corneum (hyperkeratosis), often alternating with areas of epidermal thinning (atrophy).
  • Neutrophilic microabscesses: Small collections of neutrophils are present within the epidermis and dermis, indicative of an inflammatory response. Crucially, these microabscesses often contain muriform cells.
  • Dermal granulomas: Granulomas, clusters of immune cells attempting to wall off the infection, are found in the dermis. These granulomas are typically composed of epithelioid cells, macrophages, and giant cells.
  • Increased dermal capillaries: An increased number of blood vessels in the dermis reflects the inflammatory and proliferative nature of the lesion.
  • Variable dermal fibrosis: Depending on the duration and severity of the infection, varying degrees of fibrosis (scarring) are present in the dermis, often associated with mononuclear inflammatory cells such as histiocytes, plasma cells, and lymphocytes.

Image: Microscopic view of skin tissue infected with chromomycosis, showing pigmented sclerotic bodies, a key diagnostic feature.

However, the most pathognomonic and diagnostically significant finding is the presence of sclerotic bodies (also known as medlar bodies, muriform cells, or copper pennies) within the dermis. These are thick-walled, spherical to oval, chestnut-brown cells, typically measuring 5-15 μm in diameter. They are often described as resembling “copper pennies” or “Medlar fruits” due to their color and morphology. Sclerotic bodies may be found singly or in clusters, both extracellularly and within giant cells or macrophages. Their presence is essential for confirming chromoblastomycosis diagnosis histopathologically. The tissue surrounding the sclerotic bodies may exhibit varying degrees of fibrosis, granulomatous inflammation, and, in cases of ulceration, secondary bacterial infection.

History and Physical Examination in Chromoblastomycosis Diagnosis

A thorough history and physical examination are crucial steps in the evaluation process leading to chromoblastomycosis diagnosis. The clinical presentation of chromoblastomycosis is often variable, but understanding the typical progression and risk factors is essential.

The infection usually begins following a skin injury, often in an outdoor setting with exposure to soil, wood, or plant material. Patients may not always recall a specific traumatic event, as the inoculation can be minor and unnoticed. The initial lesion typically starts as a small, inconspicuous pink-to-red macule or papule at the site of inoculation. Over time, and often very slowly, the lesion evolves through a series of morphological changes. These changes can include:

  • Verrucous papules: Raised, wart-like lesions are a common presentation.
  • Nodules: Solid, raised bumps may develop.
  • Scaly plaques: Patches of thickened, scaly skin can form.
  • Tumors: Exophytic or ulcerative tumors, often described as cauliflower-like masses, represent more advanced stages.
  • Cicatricial plaques: Scar-like, flattened lesions may also occur.

The lower extremities, particularly the feet and legs, are the most commonly affected areas due to their greater likelihood of trauma and environmental exposure. Most patients have a history of residence in or travel to tropical or subtropical regions, although cases can occur in non-endemic areas. The disease typically follows an indolent course, progressing slowly over weeks, months, or even years before patients seek medical attention.

During the physical examination, it is important to carefully assess the characteristics of the skin lesion(s), including:

  • Morphology: Note the shape, size, and type of lesion (macule, papule, plaque, nodule, tumor, ulcer).
  • Location: Document the anatomical site(s) involved.
  • Extent: Determine the size and number of lesions, and whether there are satellite lesions or evidence of lymphatic spread.
  • Palpation: Assess the consistency of the lesion (e.g., firm, soft, verrucous).
  • Presence of black dots: Look for characteristic black dots on the surface of the lesion, which are sclerotic bodies extruding through the epidermis.

History taking should focus on identifying risk factors and excluding differential diagnoses. Key questions to ask patients include:

  • Travel history: Recent or past travel to endemic tropical or subtropical regions.
  • Occupational history: Occupation involving outdoor work, agriculture, gardening, or forestry.
  • History of trauma: Any history of skin injuries, particularly those involving contact with soil or plant material.
  • Outdoor activities: Participation in outdoor recreation such as hiking or camping.
  • Exposure to environment: Exposure of skin to soil, particularly volcanic soil, or walking barefoot in endemic areas.
  • Past medical history: History of prior surgeries, skin conditions (e.g., squamous cell carcinoma, keloids), malignancies (e.g., mycosis fungoides), other infections (bacterial, fungal, viral, protozoan), or inflammatory diseases (e.g., lupus, sarcoidosis).
  • Family history: Family history of fungal infections.
  • Symptoms: Presence of pruritus (itching), pain, or other symptoms associated with the lesion.

It is important to note that the absence of a clear history of trauma or travel to endemic areas does not rule out chromoblastomycosis, as patients may not recall minor injuries or exposures.

Evaluation and Diagnostic Procedures for Chromoblastomycosis

The evaluation for chromoblastomycosis diagnosis involves a combination of clinical assessment and laboratory investigations. When chromoblastomycosis is suspected based on clinical presentation and history, several diagnostic procedures can be employed to confirm the diagnosis and differentiate it from other conditions.

Dermoscopy: Dermoscopy, a non-invasive skin examination technique using a handheld microscope, can be a valuable tool in the initial evaluation. Dermoscopic examination may reveal characteristic “black dots” or “cayenne pepper spots” on the lesion surface, which correspond to sclerotic bodies within the epidermis. These findings are suggestive of chromoblastomycosis and can guide further diagnostic steps.

Potassium Hydroxide (KOH) Stain: A simple and rapid diagnostic test involves scraping the surface of the lesion and examining the scrapings under a microscope after applying a KOH solution. KOH dissolves keratin, making fungal elements more visible. In chromoblastomycosis, KOH preparation may reveal the characteristic sclerotic bodies, appearing as thick-walled, pigmented cells. While KOH examination can provide a quick presumptive chromoblastomycosis diagnosis, it is less sensitive than histopathology and fungal culture.

Skin Biopsy: Skin biopsy is the gold standard for chromoblastomycosis diagnosis. A punch biopsy or excisional biopsy is typically performed to obtain tissue for both histopathological examination and fungal culture. The biopsy specimen is divided; one part is processed for histopathology, and the other is sent for fungal culture.

  • Histopathology: As described previously, histopathological examination of the biopsy specimen is crucial for confirming the diagnosis. The presence of sclerotic bodies within granulomas, along with other characteristic features such as pseudoepitheliomatous hyperplasia and neutrophilic microabscesses, is diagnostic of chromoblastomycosis. Special stains, such as Periodic acid–Schiff (PAS) stain or Gomori methenamine silver (GMS) stain, can enhance the visualization of fungal elements. Calcofluor white stain, a fluorescent dye that binds to chitin in fungal cell walls, can be used if fungal elements are difficult to identify with routine stains.

  • Fungal Culture: Fungal culture is essential for identifying the specific fungal species causing the infection. The biopsy specimen is inoculated onto fungal culture media, such as Sabouraud dextrose agar, with and without antibiotics to inhibit bacterial growth. Cultures are incubated at room temperature and observed for fungal growth over several weeks. Identification of the fungal genus and species is typically based on macroscopic and microscopic morphology of the fungal colonies and, increasingly, molecular methods such as PCR and DNA sequencing for accurate species identification.

Serological Tests: Serological tests, such as enzyme-linked immunosorbent assay (ELISA), to detect antibodies against chromoblastomycosis fungi have been developed and used in research settings. However, these tests are not commercially available for routine chromoblastomycosis diagnosis and management. Serology may have a role in epidemiological studies and monitoring treatment response in research protocols.

In summary, chromoblastomycosis diagnosis relies on a combination of clinical suspicion, dermoscopic findings, KOH examination, and, most importantly, histopathological confirmation and fungal culture of a skin biopsy. These diagnostic modalities allow for accurate identification of chromoblastomycosis and differentiation from other similar-appearing conditions.

Figure

Chromoblastomycosis DermNet New Zealand
Image: Clinical presentation of chromoblastomycosis showing typical verrucous lesions on the leg.

Treatment and Management of Chromoblastomycosis

Chromoblastomycosis treatment strategies are guided by the severity and extent of the infection, considering factors such as lesion size, number, location, presence of complications, and prior treatment history. Due to the chronic nature of chromoblastomycosis and the inherent resistance of dematiaceous fungi to many antifungal agents, treatment can be prolonged and challenging.

Severity Classification: Chromoblastomycosis is generally classified into mild, moderate, and severe disease to guide treatment decisions:

  • Mild Disease: Characterized by small, localized lesions, typically scales or nodules less than 5 cm in diameter.
  • Moderate Disease: Involves single or multiple lesions, which may be verrucous, tumoral, or plaque-like, located in one or two adjacent body areas, and up to 15 cm in diameter.
  • Severe Disease: Extensive disease with single or multiple lesions covering a large area beyond moderate disease criteria, often with complications.

Treatment Options:

Mild Disease: For mild chromoblastomycosis, procedural interventions are often the primary treatment modality.

  • Surgical Excision: Surgical removal of the lesion with a 5-mm margin of healthy tissue is effective for small, localized lesions. Complete excision aims to eliminate the fungal infection and prevent lymphatic spread. Mohs micrographic surgery may be considered in certain cases for precise tissue removal and maximal tissue preservation. Skin grafting may be necessary to close larger surgical defects.

  • Cryotherapy: Cryosurgery, using liquid nitrogen to freeze and destroy infected tissue, can be used for smaller lesions. Multiple treatment sessions may be required.

  • Local Heat Therapy: Applying heat to temperatures above 46°C can have fungicidal effects. Local heat therapy devices are available for targeted treatment.

  • Laser Therapy: Various laser modalities, such as long-pulsed 1064-nm Nd:YAG laser and carbon dioxide fractional laser, have shown promise in treating chromoblastomycosis, often in combination with antifungal medications.

  • Photodynamic Therapy (PDT): PDT, using photosensitizing agents and light activation, has been explored as a treatment option, particularly in combination with retinoids.

Procedural interventions may be used alone for mild disease or in conjunction with oral antifungal medications, especially in cases where complete excision is not feasible or to reduce the risk of recurrence.

Moderate-to-Severe Disease: For more extensive or severe chromoblastomycosis, systemic antifungal therapy is typically required, often in combination with procedural interventions.

  • Antifungal Medications: The primary antifungal drugs recommended for chromoblastomycosis are terbinafine and itraconazole. Dual oral therapy combining terbinafine (250-500 mg/day) and itraconazole (200-400 mg/day) is often employed for enhanced efficacy. These medications are typically administered for prolonged periods, often several months, and treatment duration depends on clinical response and lesion resolution.

    • Terbinafine: Terbinafine is an allylamine antifungal that inhibits fungal squalene epoxidase, disrupting ergosterol synthesis. It is generally well-tolerated but can cause hepatotoxicity, requiring liver function monitoring.

    • Itraconazole: Itraconazole is a triazole antifungal that inhibits fungal cytochrome P450 enzymes, also affecting ergosterol synthesis. It has a broader spectrum of activity against dematiaceous fungi and is often effective in chromoblastomycosis. Drug-drug interactions are a concern with itraconazole, and monitoring is recommended.

Other antifungal agents that have been used in chromoblastomycosis treatment, often in cases refractory to first-line agents, include:

  • Voriconazole: Voriconazole, another triazole antifungal, has shown activity against chromoblastomycosis fungi and may be used in severe or refractory cases.

  • Posaconazole: Posaconazole, a broader-spectrum triazole, may be an alternative option in difficult-to-treat cases.

  • Amphotericin B: Amphotericin B, a polyene antifungal, has been used historically, often via local injection into lesions, but is less commonly used systemically due to toxicity and the availability of more targeted antifungals.

  • Flucytosine (5-FC): Flucytosine is an antimetabolite antifungal that may be used in combination with itraconazole or amphotericin B for synergistic effect in severe cases.

  • Imiquimod: Topical imiquimod, an immune response modifier, has been used as adjunctive therapy to stimulate local immune response against the fungus.

  • Acitretin: Acitretin, a systemic retinoid, has been used in combination with antifungal agents to improve treatment outcomes, possibly by reducing hyperkeratosis and enhancing drug penetration.

Adjunctive Therapies:

  • Immunotherapy: Glucan, an immunostimulant, has been explored as adjunctive therapy to enhance host immune response.

  • Combination Therapy: Combining antifungal agents with different mechanisms of action or combining antifungals with procedural interventions is often employed to improve efficacy and overcome antifungal resistance.

Monitoring and Follow-up: Long-term monitoring is essential after initiating treatment and even after achieving clinical resolution. Regular follow-up visits are necessary to assess treatment response, monitor for adverse effects of medications, and detect any signs of recurrence. Skin biopsies with culture and fungal assessments may be performed during follow-up to confirm mycological cure. Treatment duration is highly variable and can range from several months to years, depending on disease severity and response to therapy.

Differential Diagnosis of Chromoblastomycosis

The differential diagnosis of chromoblastomycosis is broad, as its clinical presentation can mimic various infectious and non-infectious conditions. Accurate chromoblastomycosis diagnosis requires careful consideration of these differential diagnoses to ensure appropriate management.

Infectious Diseases:

  • Other Fungal Infections:

    • Lobomycosis: Another chronic fungal infection of the skin, primarily found in the Amazon basin.
    • Phaeohyphomycosis: Infections caused by other dematiaceous fungi, but often presenting with different clinical and histopathological features.
    • Eumycetoma (Madura Foot): Chronic subcutaneous infection caused by fungi or bacteria, characterized by swelling, draining sinuses, and granules.
    • Blastomycosis: Systemic fungal infection that can present with cutaneous lesions, particularly in endemic areas.
    • Coccidioidomycosis: Systemic fungal infection, also with potential skin manifestations, prevalent in arid regions of the Americas.
    • Sporotrichosis: Subcutaneous fungal infection often presenting with lymphatic spread, resembling a sporotrichoid pattern.
    • Majocchi Granuloma: Fungal infection of the dermis and subcutaneous tissue, often due to dermatophytes.
    • Paracoccidioidomycosis (South American Blastomycosis): Systemic mycosis endemic to Latin America, with mucocutaneous involvement.

  • Bacterial Infections:

    • Tuberculosis Verrucosa Cutis: Cutaneous tuberculosis presenting with wart-like lesions.
    • Actinomycetoma: Bacterial mycetoma caused by Actinomyces bacteria.
    • Botryomycosis: Chronic bacterial infection of the skin and subcutaneous tissue, mimicking mycetoma.
    • Cutaneous Syphilis (Secondary Syphilis): Skin lesions of secondary syphilis can be varied and may resemble chromoblastomycosis.
    • Yaws: Tropical infection caused by Treponema pallidum pertenue, with skin lesions.
    • Nontuberculous Mycobacterial Infections: Skin infections caused by mycobacteria other than Mycobacterium tuberculosis.

  • Viral Infections:

    • Verruca Vulgaris (Common Warts): Viral warts caused by human papillomavirus (HPV).
    • Papilloma: Benign epithelial tumors caused by HPV.

  • Protozoan Infections:

    • Cutaneous Leishmaniasis: Protozoan infection transmitted by sandflies, causing skin ulcers and nodules.
    • Rhinosporidiosis: Chronic infection caused by Rhinosporidium seeberi, affecting mucous membranes and skin.

  • Helminthic Infections:

    • Filariasis: Parasitic infection causing lymphatic obstruction and lymphedema, which can resemble advanced chromoblastomycosis.

  • Algal Infections:

    • Protothecosis: Rare infection caused by algae of the genus Prototheca, can cause skin lesions.

Non-infectious Conditions:

  • Skin Cancers:

    • Melanoma: Malignant skin cancer that can sometimes mimic verrucous lesions.
    • Squamous Cell Carcinoma: Skin cancer, particularly keratoacanthoma variant, may resemble chromoblastomycosis.

  • Benign Skin Lesions:

    • Keloids: Hypertrophic scars that can become raised and nodular.
    • Sarcoidosis: Systemic granulomatous disease that can involve the skin.
    • Podoconiosis (Elephantiasis Nonfilarial): Non-infectious lymphedema of the lower limbs caused by soil irritants.
    • Systemic Lupus Erythematosus (SLE): Certain cutaneous manifestations of SLE may resemble chromoblastomycosis.

A careful clinical evaluation, coupled with appropriate laboratory investigations, particularly histopathology and fungal culture, is essential to differentiate chromoblastomycosis from these conditions and establish an accurate chromoblastomycosis diagnosis.

Prognosis of Chromoblastomycosis

The prognosis of chromoblastomycosis is generally favorable with appropriate and timely treatment, although cure can be challenging, and relapses are possible. Early chromoblastomycosis diagnosis and initiation of treatment are crucial to improve outcomes and minimize morbidity.

Chromoblastomycosis is primarily a localized cutaneous and subcutaneous infection, and systemic dissemination is rare, except in severely immunocompromised individuals. Therefore, mortality directly attributable to chromoblastomycosis is uncommon. However, untreated or inadequately treated chromoblastomycosis can lead to significant morbidity and reduced quality of life due to chronic lesions, complications, and functional impairment.

Factors that can influence prognosis include:

  • Disease Severity and Extent: Mild, localized disease generally has a better prognosis compared to extensive, long-standing, or complicated infections.
  • Treatment Adherence and Response: Patient compliance with prolonged treatment regimens and the response of the fungal species to antifungal agents are critical.
  • Host Immune Status: Immunocompromised individuals may have a less favorable prognosis and increased risk of treatment failure or relapse.
  • Complications: Development of complications such as fibrosis, secondary bacterial infections, lymphedema, or malignant transformation can worsen the prognosis.

With appropriate treatment, including surgical excision for mild cases and antifungal therapy for moderate-to-severe disease, clinical improvement and lesion resolution can be achieved in many patients. However, mycological cure, defined as the complete eradication of the fungus from the tissue, can be difficult to attain, and persistent sclerotic bodies may remain even after clinical improvement. Long-term follow-up is essential to monitor for recurrence and manage any residual disease or complications. Relapses can occur, particularly in cases with incomplete treatment or persistent fungal elements. Regular monitoring and prompt retreatment are necessary in such instances.

Complications of Chromoblastomycosis

Untreated or poorly managed chromoblastomycosis can lead to various complications, which can significantly impact patient morbidity and quality of life. Common complications include:

  • Scarring: Atrophic scarring is a frequent sequela of chromoblastomycosis lesions, even after successful treatment.
  • Tissue Fibrosis: Chronic inflammation and granulomatous reaction can result in disabling tissue fibrosis, leading to skin thickening, contractures, and functional limitations. Fibrosis around joints can cause joint immobility, and eyelid involvement can lead to ectropion.
  • Ulceration: Chronic lesions may ulcerate, causing pain, secondary bacterial infections, and delayed healing.
  • Secondary Bacterial Infection: Ulcerated chromoblastomycosis lesions are prone to secondary bacterial infections, which can exacerbate inflammation and complicate management.
  • Lymphatic Spread: In rare cases, chromoblastomycosis can spread along lymphatic channels, mimicking sporotrichosis, with the development of nodular lesions along lymphatic vessels.
  • Lymphedema and Elephantiasis: Chronic lymphatic obstruction due to fibrosis can lead to lymphedema, which, in severe cases, can progress to elephantiasis, characterized by massive swelling and disfigurement of the affected limb.
  • Malignant Transformation: Although rare, malignant transformation of chronic chromoblastomycosis lesions to squamous cell carcinoma has been reported. Long-standing, untreated lesions may have a slightly increased risk of malignant degeneration.
  • Disseminated Disease: Systemic dissemination of chromoblastomycosis is exceedingly rare and usually occurs only in severely immunocompromised patients.

Preventing complications requires early chromoblastomycosis diagnosis, prompt initiation of appropriate treatment, and diligent long-term management. Patient education on wound care, hygiene, and adherence to treatment regimens is crucial to minimize the risk of complications and improve outcomes.

Deterrence and Patient Education for Chromoblastomycosis

Preventing chromoblastomycosis primarily involves minimizing the risk of skin trauma and exposure to environments where dematiaceous fungi are prevalent, particularly in endemic areas. Patient education plays a vital role in deterrence and self-management. Key preventive measures and patient education points include:

  • Avoidance of Cutaneous Trauma: Educate individuals, especially those in endemic regions and engaged in agricultural or outdoor activities, on the importance of avoiding skin injuries. Use caution when working with wood, soil, and vegetation.

  • Protective Clothing and Footwear: Recommend wearing protective clothing, including long sleeves, long pants, and gloves, when working outdoors or in agricultural settings. Wearing closed shoes or boots can prevent foot injuries and exposure to soil.

  • Wound Care: Advise prompt and thorough cleaning of any skin wounds, cuts, or punctures, especially those acquired outdoors. Use antiseptic solutions and cover wounds with dressings to prevent fungal contamination.

  • Environmental Awareness: Educate individuals about the risk of chromoblastomycosis in endemic tropical and subtropical areas, particularly in rural agricultural environments. Raising awareness can promote preventive behaviors.

  • Early Medical Attention: Encourage individuals to seek medical attention promptly if they develop any suspicious skin lesions, especially after potential skin trauma in endemic areas. Early chromoblastomycosis diagnosis and treatment are crucial to prevent disease progression and complications.

  • Treatment Adherence: For patients diagnosed with chromoblastomycosis, emphasize the importance of adhering to the prescribed treatment regimen, which often involves prolonged antifungal therapy. Explain the rationale for long-term treatment and the potential consequences of non-compliance.

  • Medication Education: Provide thorough education on prescribed medications, including dosage, administration, potential side effects, and drug interactions. Address patient concerns and ensure they understand the importance of completing the full course of treatment.

  • Follow-up Care: Stress the need for regular follow-up appointments to monitor treatment response, detect recurrence, and manage any complications. Explain that long-term follow-up is essential even after clinical resolution.

Currently, there is no commercially available vaccine for chromoblastomycosis. Research efforts are ongoing to develop potential vaccine candidates, but prevention relies primarily on avoidance of exposure and early treatment. Effective patient education and public health initiatives in endemic regions are crucial for reducing the burden of chromoblastomycosis.

Enhancing Healthcare Team Outcomes in Chromoblastomycosis Management

Optimal management of chromoblastomycosis requires a collaborative, interprofessional healthcare team approach. Effective coordination and communication among various specialists are essential to ensure comprehensive patient care and improve outcomes. The healthcare team may include:

  • Dermatologist: Plays a central role in initial evaluation, chromoblastomycosis diagnosis, skin biopsy, and management of cutaneous lesions.
  • Infectious Disease Specialist: Provides expertise in fungal infections, antifungal therapy selection and management, and management of complex or refractory cases.
  • Surgeon: May be involved in surgical excision of localized lesions or debridement of extensive lesions.
  • Pathologist: Essential for histopathological chromoblastomycosis diagnosis and identification of sclerotic bodies in skin biopsy specimens.
  • Microbiologist: Performs fungal cultures and identification of causative fungal species.
  • Wound Care Nurse: Provides specialized wound care for ulcerated lesions and educates patients on wound management techniques.
  • Pharmacist: Ensures appropriate antifungal medication selection, dosing, drug interaction management, and patient counseling on medication use and side effects.
  • Primary Care Physician/Internist: Provides ongoing medical care, monitors overall patient health, and coordinates referrals to specialists.
  • Public Health Professionals: In endemic regions, public health initiatives are crucial for disease surveillance, prevention education, and community outreach.

Effective interprofessional communication is vital for coordinating diagnostic procedures, treatment planning, and follow-up care. Regular team meetings, shared electronic health records, and clear communication protocols can enhance care coordination. Patient education should be a shared responsibility of the healthcare team, with consistent messaging and reinforcement of key preventive and management strategies. By working collaboratively, the interprofessional team can optimize chromoblastomycosis diagnosis, treatment, and long-term management, ultimately improving patient outcomes and quality of life in this challenging neglected tropical disease.

Conclusion

Chromoblastomycosis is a chronic, debilitating fungal infection that poses a significant health challenge in tropical and subtropical regions. Accurate and timely chromoblastomycosis diagnosis is paramount for effective management and preventing complications. Healthcare professionals should maintain a high index of suspicion for chromoblastomycosis in patients presenting with chronic verrucous skin lesions, particularly those with a history of residence in or travel to endemic areas or occupational/recreational exposures. Diagnostic modalities, including dermoscopy, KOH examination, histopathology, and fungal culture, are essential for confirmation. Treatment strategies are tailored to disease severity, ranging from surgical excision for mild cases to prolonged antifungal therapy for moderate-to-severe infections. Interprofessional collaboration, patient education, and long-term follow-up are critical components of comprehensive chromoblastomycosis management. Continued research efforts are needed to develop more effective diagnostic tools, treatment options, and preventive strategies for this neglected tropical disease.

References

  1. Hartsough EM, Foreman RK, Martinez-Lage M, Branda J, Sohani AR, Zukerberg L. Dematiaceous fungal infections: clinical and pathologic conundrums. J Clin Pathol. 2024 Apr 18;77(5):352-357. PubMed: 38272660
  2. Shenoy MM, Girisha BS, Krishna S. Chromoblastomycosis: A Case Series and Literature Review. Indian Dermatol Online J. 2023 Sep-Oct;14(5):665-669. PMC free article: PMC10506812 PubMed: 37727562
  3. Borman AM, Fraser M, Patterson Z, Linton CJ, Palmer M, Johnson EM. Fungal Infections of Implantation: More Than Five Years of Cases of Subcutaneous Fungal Infections Seen at the UK Mycology Reference Laboratory. J Fungi (Basel). 2022 Mar 25;8(4) PMC free article: PMC9028115 PubMed: 35448574
  4. Khan S, Khan M, Khan F, Ahmad Z, Zia-Ur-Rehman A. A Rare Case of Chromoblastomycosis in a 12-year-old boy. J Pak Med Assoc. 2019 Sep;69(9):1390-1393. PubMed: 31511733
  5. Mugleston BJ, Usatine RP, Rosen T. Wide Morphologic Variability of Chromoblastomycosis in the Western Hemisphere. Skinmed. 2016;14(6):423-427. PubMed: 28031127
  6. Enbiale W, Bekele A, Manaye N, Seife F, Kebede Z, Gebremeskel F, van Griensven J. Subcutaneous mycoses: Endemic but neglected among the Neglected Tropical Diseases in Ethiopia. PLoS Negl Trop Dis. 2023 Sep;17(9):e0011363. PMC free article: PMC10561858 PubMed: 37756346
  7. Garzon LM, Rueda LJ, Celis AM, Cardenas M, Guevara-Suarez M. Exophiala psychrophila: A new agent of chromoblastomycosis. Med Mycol Case Rep. 2019 Mar;23:31-33. PMC free article: PMC6263014 PubMed: 30533349
  8. Torres E, Beristain JG, Lievanos Z, Arenas R. Chromoblastomycosis associated with a lethal squamous cell carcinoma. An Bras Dermatol. 2010 Mar-Apr;85(2):267-70. PubMed: 20520950
  9. Rios JE, Paiva CB, Paula GM, Figueiredo WR, Arantes JC, Almeida FM, Limongi RM. Chromomycosis, an unusual cause of cicatricial ectropion: a case report. Arq Bras Oftalmol. 2017 Jan-Feb;80(1):46-48. PubMed: 28380102
  10. Potenciano da Silva KL, Moraes D, Lechner B, Lindner H, Haas H, Almeida Soares CM, Silva-Bailão MG, Bailão AM. Fonsecaea pedrosoi produces ferricrocin and can utilize different host iron sources. Fungal Biol. 2023 Dec;127(12):1512-1523. PubMed: 38097325
  11. Abadías-Granado I, Gómez-Mateo MC, Stchigel AM, López C. Chromoblastomycosis due to Cladophialophora immunda: An emerging pathogen in immunocompromised patients? Enferm Infecc Microbiol Clin (Engl Ed). 2023 Jan;41(1):51-53. PubMed: 36443189
  12. Abliz P, Fukushima K, Takizawa K, Nishimura K. Identification of pathogenic dematiaceous fungi and related taxa based on large subunit ribosomal DNA D1/D2 domain sequence analysis. FEMS Immunol Med Microbiol. 2004 Jan 15;40(1):41-9. PubMed: 14734185
  13. Voidaleski MF, Gomes RR, Azevedo CMPES, Lima BJFS, Costa FF, Bombassaro A, Fornari G, Cristina Lopes da Silva I, Andrade LV, Lustosa BPR, Najafzadeh MJ, de Hoog GS, Vicente VA. Environmental Screening of Fonsecaea Agents of Chromoblastomycosis Using Rolling Circle Amplification. J Fungi (Basel). 2020 Nov 17;6(4) PMC free article: PMC7712894 PubMed: 33212756
  14. Sudhadham M, de Hoog GS, Menken SB, Gerrits van den Ende AH, Sihanonth P. Rapid screening for genotypes as possible markers of virulence in the neurotropic black yeast Exophiala dermatitidis using PCR-RFLP. J Microbiol Methods. 2010 Feb;80(2):138-42. PubMed: 19961882
  15. Ahmed SA, Bonifaz A, González GM, Moreno LF, Menezes da Silva N, Vicente VA, Li R, de Hoog S. Chromoblastomycosis Caused by Phialophora-Proven Cases from Mexico. J Fungi (Basel). 2021 Jan 29;7(2) PMC free article: PMC7910919 PubMed: 33572699
  16. González GM, Rojas OC, González JG, Kang Y, de Hoog GS. Chromoblastomycosis caused by Rhinocladiella aquaspersa. Med Mycol Case Rep. 2013 Aug 31;2:148-51. PMC free article: PMC3885939 PubMed: 24432242
  17. Ibrahim-Granet O, de Bièvre C. Study of the conidial development and cleistothecium-like structure of some strains of Fonsecaea pedrosoi. Comparison with other close Dematiaeae. Mycopathologia. 1984 Feb 15;84(2-3):181-6. PubMed: 6538933
  18. Guevara A, Nery AF, de Souza Carvalho Melhem M, Bonfietti L, Rodrigues AM, Hagen F, de Carvalho JA, de Camargo ZP, de Souza Lima BJF, Vicente VA, Hahn RC. Molecular epidemiology and clinical-laboratory aspects of chromoblastomycosis in Mato Grosso, Brazil. Mycoses. 2022 Dec;65(12):1146-1158. PMC free article: PMC9828117 PubMed: 35869803
  19. Queiroz-Telles F. CHROMOBLASTOMYCOSIS: A NEGLECTED TROPICAL DISEASE. Rev Inst Med Trop Sao Paulo. 2015 Sep;57 Suppl 19(Suppl 19):46-50. PMC free article: PMC4711190 PubMed: 26465369
  20. Guevara A, Siqueira NP, Nery AF, Cavalcante LRDS, Hagen F, Hahn RC. Chromoblastomycosis in Latin America and the Caribbean: Epidemiology over the past 50 years. Med Mycol. 2021 Dec 08;60(1) PubMed: 34637525
  21. Verma S, Thakur BK, Raphael V, Thappa DM. Epidemiology of Subcutaneous Mycoses in Northeast India: A Retrospective Study. Indian J Dermatol. 2018 Nov-Dec;63(6):496-501. PMC free article: PMC6233045 PubMed: 30504979
  22. Ray A, Aayilliath K A, Banerjee S, Chakrabarti A, Denning DW. Burden of Serious Fungal Infections in India. Open Forum Infect Dis. 2022 Dec;9(12):ofac603. PMC free article: PMC9792086 PubMed: 36589484
  23. Santos DWCL, de Azevedo CMPES, Vicente VA, Queiroz-Telles F, Rodrigues AM, de Hoog GS, Denning DW, Colombo AL. The global burden of chromoblastomycosis. PLoS Negl Trop Dis. 2021 Aug;15(8):e0009611. PMC free article: PMC8360387 PubMed: 34383752
  24. Queiroz-Telles F, de Hoog S, Santos DW, Salgado CG, Vicente VA, Bonifaz A, Roilides E, Xi L, Azevedo CM, da Silva MB, Pana ZD, Colombo AL, Walsh TJ. Chromoblastomycosis. Clin Microbiol Rev. 2017 Jan;30(1):233-276. PMC free article: PMC5217794 PubMed: 27856522
  25. López Martínez R, Méndez Tovar LJ. Chromoblastomycosis. Clin Dermatol. 2007 Mar-Apr;25(2):188-94. PubMed: 17350498
  26. Passero LFD, Cavallone IN, Belda W. Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis. J Immunol Res. 2021;2021:9742832. PMC free article: PMC8575639 PubMed: 34761009
  27. Brito AC, Bittencourt MJS. Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update. An Bras Dermatol. 2018 Jul-Aug;93(4):495-506. PMC free article: PMC6063100 PubMed: 30066754
  28. Queiroz-Telles F, Fahal AH, Falci DR, Caceres DH, Chiller T, Pasqualotto AC. Neglected endemic mycoses. Lancet Infect Dis. 2017 Nov;17(11):e367-e377. PubMed: 28774696
  29. Peltroche-Llacsahuanga H, Schnitzler N, Jentsch S, Platz A, De Hoog S, Schweizer KG, Haase G. Analyses of phagocytosis, evoked oxidative burst, and killing of black yeasts by human neutrophils: a tool for estimating their pathogenicity? Med Mycol. 2003 Feb;41(1):7-14. PubMed: 12627799
  30. Rozental S, Alviano CS, de Souza W. The in vitro susceptibility of Fonsecaea pedrosoi to activated macrophages. Mycopathologia. 1994 May;126(2):85-91. PubMed: 8065435
  31. Kneipp LF, Magalhães AS, Abi-Chacra EA, Souza LO, Alviano CS, Santos AL, Meyer-Fernandes JR. Surface phosphatase in Rhinocladiella aquaspersa: biochemical properties and its involvement with adhesion. Med Mycol. 2012 Aug;50(6):570-8. PubMed: 22320857
  32. Palmeira VF, Goulart FRV, Granato MQ, Alviano DS, Alviano CS, Kneipp LF, Santos ALS. Fonsecaea pedrosoi Sclerotic Cells: Secretion of Aspartic-Type Peptidase and Susceptibility to Peptidase Inhibitors. Front Microbiol. 2018;9:1383. PMC free article: PMC6033999 PubMed: 30008700
  33. Montoya AM, Montesino CA, Carrión-Álvarez D, González GM, Rojas OC. A comparative study of extracellular enzymes from chromoblastomycosis agents reveals the potential association of phospholipase with the severity of the lesions. Microb Pathog. 2020 Oct;147:104367. PubMed: 32649963
  34. Palmeira VF, Kneipp LF, Alviano CS, dos Santos AL. Phospholipase and esterase production by clinical strains of Fonsecaea pedrosoi and their interactions with epithelial cells. Mycopathologia. 2010 Jul;170(1):31-7. PubMed: 20195904
  35. Siqueira IM, de Castro RJA, Leonhardt LCM, Jerônimo MS, Soares AC, Raiol T, Nishibe C, Almeida N, Tavares AH, Hoffmann C, Bocca AL. Modulation of the immune response by Fonsecaea pedrosoi morphotypes in the course of experimental chromoblastomycosis and their role on inflammatory response chronicity. PLoS Negl Trop Dis. 2017 Mar;11(3):e0005461. PMC free article: PMC5391973 PubMed: 28355277
  36. Ricard-Blum S, Esterre P, Grimaud JA. Collagen cross-linking by pyridinoline occurs in non-reversible skin fibrosis. Cell Mol Biol (Noisy-le-grand). 1993 Nov;39(7):723-7. PubMed: 8268758
  37. Torinuki W, Okohchi K, Takematsu H, Tagami H. Activation of the alternative complement pathway by Fonsecaea pedrosoi. J Invest Dermatol. 1984 Oct;83(4):308-10. PubMed: 6481182
  38. Breda LCD, Breda CNS, de Almeida JRF, Paulo LNM, Jannuzzi GP, Menezes IG, Albuquerque RC, Câmara NOS, Ferreira KS, de Almeida SR. Fonsecaeapedrosoi Conidia and Hyphae Activate Neutrophils Distinctly: Requirement of TLR-2 and TLR-4 in Neutrophil Effector Functions. Front Immunol. 2020;11:540064. PMC free article: PMC7609859 PubMed: 33193308
  39. Bocca AL, Brito PP, Figueiredo F, Tosta CE. Inhibition of nitric oxide production by macrophages in chromoblastomycosis: a role for Fonsecaea pedrosoi melanin. Mycopathologia. 2006 Apr;161(4):195-203. PubMed: 16552481
  40. Zhang J, Wang L, Xi L, Huang H, Hu Y, Li X, Huang X, Lu S, Sun J. Melanin in a meristematic mutant of Fonsecaea monophora inhibits the production of nitric oxide and Th1 cytokines of murine macrophages. Mycopathologia. 2013 Jun;175(5-6):515-22. PubMed: 23054330
  41. Hayakawa M, Ghosn EE, da Gloria Teixeria de Sousa M, Ferreira KS, Almeida SR. Phagocytosis, production of nitric oxide and pro-inflammatory cytokines by macrophages in the presence of dematiaceous [correction of dematiaceus] fungi that cause chromoblastomycosis. Scand J Immunol. 2006 Oct;64(4):382-7. PubMed: 16970678
  42. Teixeira de Sousa Mda G, Ghosn EE, Almeida SR. Absence of CD4+ T cells impairs host defence of mice infected with Fonsecaea pedrosoi. Scand J Immunol. 2006 Dec;64(6):595-600. PubMed: 17083615
  43. d’Avila SC, Pagliari C, Duarte MI. The cell-mediated immune reaction in the cutaneous lesion of chromoblastomycosis and their correlation with different clinical forms of the disease. Mycopathologia. 2003;156(2):51-60. PubMed: 12733624
  44. Alves de Lima Silva A, Criado PR, Nunes RS, Kanashiro-Galo L, Seixas Duarte MI, Sotto MN, Pagliari C. Langerhans Cells Express IL-17A in the Epidermis of Chromoblastomycosis Lesions. Biomed Hub. 2017 May-Aug;2(2):1-8. PMC free article: PMC6945965 PubMed: 31988913
  45. Tsuneto LT, Arce-Gomez B, Petzl-Erler ML, Queiroz-Telles F. HLA-A29 and genetic susceptibility to chromoblastomycosis. J Med Vet Mycol. 1989;27(3):181-5. PubMed: 2778577
  46. Naranjo F, Márquez I, Gendzekhadze K, Zhang S, Fernández-Mestre M, Yegres F, Richard-Yegres N, Navas T, Montagnani S, Ogando V, Layrisse Z. Human leukocyte antigen class I and MICA haplotypes in a multicase family with Cladophialophora carrionii chromoblastomycosis. Tissue Antigens. 2006 Oct;68(4):287-92. PubMed: 17026462
  47. Huang C, Deng W, Zhang Y, Zhang K, Ma Y, Song Y, Wan Z, Wang X, Li R. CARD9 deficiency predisposing chromoblastomycosis: A case report and comparative transcriptome study. Front Immunol. 2022;13:984093. PMC free article: PMC9500462 PubMed: 36159827
  48. Sali AP, Sahay A. Chromoblastomycosis of the leg. Pol J Pathol. 2017;68(2):182-184. PubMed: 29025254
  49. Gajurel K, Ahrens WA. Medlar bodies of chromoblastomycosis. Transpl Infect Dis. 2023 Jun;25(3):e14047. PubMed: 36852755
  50. Dokic Y, Verstovsek G, Rosen T. Chromoblastomycosis Presenting as a Solitary Lesion in a Non-endemic Region. Cureus. 2023 Dec;15(12):e49791. PMC free article: PMC10758271 PubMed: 38164315
  51. Dupont C, Duong TA, Mallet S, Mamzer-Bruneel MF, Thervet E, Bougnoux ME, Dupont B. Unusual presentation of chromoblastomycosis due to Cladophialophora carrionii in a renal and pancreas transplant recipient patient successfully treated with posaconazole and surgical excision. Transpl Infect Dis. 2010 Apr;12(2):180-3. PubMed: 20002358
  52. Schieffelin JS, Garcia-Diaz JB, Loss GE, Beckman EN, Keller RA, Staffeld-Coit C, Garces JC, Pankey GA. Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment. Transpl Infect Dis. 2014 Apr;16(2):270-8. PubMed: 24628809
  53. Kimura TFE, Romera LMD, de Almeida SR. Fonsecaea pedrosoi Conidia Induces Activation of Dendritic Cells and Increases CD11c+ Cells in Regional Lymph Nodes During Experimental Chromoblastomycosis. Mycopathologia. 2020 Apr;185(2):245-256. PubMed: 32008205
  54. Shen Y, Jiang B, Zhang H, Feng J, Hua H. Combination therapy for an elderly patient with chromoblastomycosis caused by Fonsecaea monophora: a case report. Ann Transl Med. 2022 Jan;10(2):114. PMC free article: PMC8848360 PubMed: 35282094
  55. Guevara A, Vicente VA, de Souza Lima BJF, Nery AF, Hagen F, Hahn RC. Chromoblastomycosis-Leprosy Co-Infection in Central West Brazil. Presentation of Three Cases and Literature Review. Mycopathologia. 2022 Aug;187(4):363-374. PMC free article: PMC9325793 PubMed: 35764905
  56. Wang J, Zhu M, Wang P. Chromoblastomycosis by Exophiala jeanselmei associated with squamous cell carcinoma. J Mycol Med. 2021 Mar;31(1):101105. PubMed: 33422739
  57. Mutalik VS, Bissonnette C, Kalmar JR, McNamara KK. Unique Oral Presentations of Deep Fungal Infections: A Report of Four Cases. Head Neck Pathol. 2021 Jun;15(2):682-690. PMC free article: PMC8134600 PubMed: 32889592
  58. Lanzoni A, Rapparini L, Pagliara A, Misciali C, Starace M, Piraccini BM. Chromoblastomycosis, A Neglected Fungal Infection. Mycopathologia. 2023 Dec;188(6):1103-1105. PubMed: 37856009
  59. Kim JSTW, Santos FGD, Enokihara MMSES, Hirata SH, Tomimori J, Ogawa MM. Cutaneous chromoblastomycosis mimicking melanoma in a renal transplant recipient. Med Mycol Case Rep. 2022 Dec;38:41-43. PMC free article: PMC9647092 PubMed: 36393996
  60. Assefa W, Sinatayehu R, Sendeku MA, Dires M. Chromoblastomycosis: delayed diagnosis with extensive cutaneous lesions. Int J Infect Dis. 2023 Jun;131:50-52. PubMed: 36972782
  61. Hamza SH, Mercado PJ, Skelton HG, Smith KJ. An unusual dematiaceous fungal infection of the skin caused by Fonsecaea pedrosoi: a case report and review of the literature. J Cutan Pathol. 2003 May;30(5):340-3. PubMed: 12753177
  62. Sousa IS, Mello TP, Pereira EP, Granato MQ, Alviano CS, Santos ALS, Kneipp LF. Biofilm Formation by Chromoblastomycosis Fungi Fonsecaea pedrosoi and Phialophora verrucosa: Involvement with Antifungal Resistance. J Fungi (Basel). 2022 Sep 15;8(9) PMC free article: PMC9504689 PubMed: 36135688
  63. Maubon D, Garnaud C, Ramarozatovo LS, Fahafahantsoa RR, Cornet M, Rasamoelina T. Molecular Diagnosis of Two Major Implantation Mycoses: Chromoblastomycosis and Sporotrichosis. J Fungi (Basel). 2022 Apr 09;8(4) PMC free article: PMC9027143 PubMed: 35448613
  64. Borges JR, Ximenes BÁS, Miranda FTG, Peres GBM, Hayasaki IT, Ferro LCC, Ianhez M, Garcia-Zapata MTA. Accuracy of direct examination and culture as compared to the anatomopathological examination for the diagnosis of chromoblastomycosis: a systematic review. An Bras Dermatol. 2022 Jul-Aug;97(4):424-434. PMC free article: PMC9263652 PubMed: 35643736
  65. Oberto-Perdigón L, Romero H, Pérez-Blanco M, Apitz-Castro R. [An ELISA test for the study of the therapeutic evolution of chromoblastomycosis by Cladophialophora carrionii in the endemic area of Falcon State, Venezuela]. Rev Iberoam Micol. 2005 Mar;22(1):39-43. PubMed: 15813682
  66. Vidal MS, de Castro LG, Cavalecate SC, Lacaz Cda S. Immunoprecipitation techniques and Elisa in the detection of anti-Fonsecaea pedrosoi antibodies in chromoblastomycosis. Rev Inst Med Trop Sao Paulo. 2003 Nov-Dec;45(6):315-8. PubMed: 14762630
  67. Rolon AM, Tolaymat LM, Sokumbi O, Bodiford K. The Role of Excision for Treatment of Chromoblastomycosis: A Cutaneous Fungal Infection Frequently Mistaken for Squamous Cell Carcinoma. Dermatol Surg. 2023 Jul 01;49(7):649-653. PubMed: 37093678
  68. Pavlidakey GP, Snow SN, Mohs FE. Chromoblastomycosis treated by Mohs micrographic surgery. J Dermatol Surg Oncol. 1986 Oct;12(10):1073-5. PubMed: 3760315
  69. Luo J, Feng P, Hu Y, Yang Y, Zhou S, Huang S, Jadad A, Zhong Z, Zheng Y, Liu K, Lu Y, Hu Y, Zhou X. [Long-pulsed 1064 nm Nd: YAG laser combined with terbinafine against chromoblastomycosis caused by Fonsecaea nubica and the effect of laser therapy in a Wistar rat model]. Nan Fang Yi Ke Da Xue Xue Bao. 2019 Jun 30;39(6):712-717. PMC free article: PMC6743912 PubMed: 31270051
  70. Lan Y, Lu S, Zhang J. Retinoid combined with photodynamic therapy against hyperkeratotic chromoblastomycosis: A case report and literature review. Mycoses. 2021 Jan;64(1):18-23. PubMed: 32989774
  71. Tsianakas A, Pappai D, Basoglu Y, Metze D, Tietz HJ, Luger TA, Bonsmann G. Chromomycosis–successful CO2 laser vaporization. J Eur Acad Dermatol Venereol. 2008 Nov;22(11):1385-6. PubMed: 18331317
  72. Bonifaz A, Martínez-Soto E, Carrasco-Gerard E, Peniche J. Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. Int J Dermatol. 1997 Jul;36(7):542-7. PubMed: 9268758
  73. Huang TH, Lan CE. Cutaneous chromoblastomycosis effectively treated with local heat monotherapy. Clin Exp Dermatol. 2019 Jun;44(4):461-462. PubMed: 30280420
  74. Restrepo A, Gonzalez A, Gomez I, Arango M, de Bedout C. Treatment of chromoblastomycosis with itraconazole. Ann N Y Acad Sci. 1988;544:504-16. PubMed: 2850755
  75. Queiroz-Telles F, Purim KS, Fillus JN, Bordignon GF, Lameira RP, Van Cutsem J, Cauwenbergh G. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol. 1992 Nov;31(11):805-12. PubMed: 1330949
  76. Antonello VS, Appel da Silva MC, Cambruzzi E, Kliemann DA, Santos BR, Queiroz-Telles F. Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association. Rev Inst Med Trop Sao Paulo. 2010 Nov-Dec;52(6):329-31. PubMed: 21225217
  77. Polak A. Combination therapy with antifungal drugs. Mykosen Suppl. 1988;2:45-53. PubMed: 3078023
  78. Ranawaka RR, Amarasinghe N, Hewage D. Chromoblastomycosis: combined treatment with pulsed itraconazole therapy and liquid nitrogen cryotherapy. Int J Dermatol. 2009 Apr;48(4):397-400. PubMed: 19335426
  79. DERBES VJ, FRIEDMAN L, KRAFCHUK JD. Chromoblastomycosis treated by vibrapuncture injection of amphotericin B. Arch Dermatol. 1959 Sep;80:286-7. PubMed: 13816006
  80. Whiting DA. Treatment of chromoblastomycosis with high local concentrations of amphotericin B. Br J Dermatol. 1967 Jun;79(6):345-51. PubMed: 6027196
  81. Esterre P, Inzan CK, Ramarcel ER, Andriantsimahavandy A, Ratsioharana M, Pecarrere JL, Roig P. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol. 1996 Jun;134 Suppl 46:33-6; discussion 40. PubMed: 8763467
  82. Bonifaz A, Saúl A, Paredes-Solis V, Araiza J, Fierro-Arias L. Treatment of chromoblastomycosis with terbinafine: experience with four cases. J Dermatolog Treat. 2005 Feb;16(1):47-51. PubMed: 15897168
  83. Criado PR, Careta MF, Valente NY, Martins JE, Rivitti EA, Spina R, Belda W. Extensive long-standing chromomycosis due to Fonsecaea pedrosoi: three cases with relevant improvement under voriconazole therapy. J Dermatolog Treat. 2011 Jun;22(3):167-74. PubMed: 20666671
  84. Yu J, Li R, Zhang M, Liu L, Wan Z. In vitro interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China. Med Mycol. 2008 Nov;46(7):745-7. PubMed: 18608889
  85. da Silva Hellwig AH, Heidrich D, Zanette RA, Scroferneker ML. In vitro susceptibility of chromoblastomycosis agents to antifungal drugs: A systematic review. J Glob Antimicrob Resist. 2019 Mar;16:108-114. PubMed: 30266638
  86. Lima AM, Sacht GL, Paula LZ, Aseka GK, Goetz HS, Gheller MF, Torraca PF. Response of chromoblastomycosis to voriconazole. An Bras Dermatol. 2016 Sep-Oct;91(5):679-681. PMC free article: PMC5087237 PubMed: 27828652
  87. de Sousa Mda G, Belda W, Spina R, Lota PR, Valente NS, Brown GD, Criado PR, Benard G. Topical application of imiquimod as a treatment for chromoblastomycosis. Clin Infect Dis. 2014 Jun;58(12):1734-7. PMC free article: PMC4036686 PubMed: 24633683
  88. Belda W, Criado PR, Passero LFD. Successful treatment of chromoblastomycosis caused by Fonsecaea pedrosoi using imiquimod. J Dermatol. 2020 Apr;47(4):409-412. PubMed: 31960479
  89. Batbayar S, Lee DH, Kim HW. Immunomodulation of Fungal β-Glucan in Host Defense Signaling by Dectin-1. Biomol Ther (Seoul). 2012 Sep;20(5):433-45. PMC free article: PMC3762275 PubMed: 24009832
  90. Azevedo Cde M, Marques SG, Resende MA, Gonçalves AG, Santos DV, da Silva RR, de Sousa Mda G, de Almeida SR. The use of glucan as immunostimulant in the treatment of a severe case of chromoblastomycosis. Mycoses. 2008 Jul;51(4):341-4. PubMed: 18444974
  91. Belda W, Criado PR, Domingues Passero LF. Case Report: Treatment of Chromoblastomycosis with Combinations including Acitretin: A Report of Two Cases. Am J Trop Med Hyg. 2020 Nov;103(5):1852-1854. PMC free article: PMC7646813 PubMed: 32815507
  92. Heidrich D, Pagani DM, Koehler A, Alves KO, Scroferneker ML. Effect of Melanin Biosynthesis Inhibition on the Antifungal Susceptibility of Chromoblastomycosis Agents. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0054621. PMC free article: PMC8284458 PubMed: 33972246
  93. Tawade Y, Gaikwad A, Deodhar A, Bhide D, Romi E, Pradhan A, Satpute M. Uncommon presentation of chromoblastomycosis. Cutis. 2018 Jun;101(6):442;447;448. PubMed: 30063772
  94. San-Bias G, Urbina JA, Marchán E, Contreras LM, Sorais F, San-Blas F. Inhibition of Paracoccidioides brasiliensis by ajoene is associated with blockade of phosphatidylcholine biosynthesis. Microbiology (Reading). 1997 May;143 ( Pt 5):1583-1586. PubMed: 9168609
  95. Sharma N, Marfatia YS. Genital elephantiasis as a complication of chromoblastomycosis: A diagnosis overlooked. Indian J Sex Transm Dis AIDS. 2009 Jan;30(1):43-5. PMC free article: PMC3168040 PubMed: 21938115
  96. de Azevedo CM, Gomes RR, Vicente VA, Santos DW, Marques SG, do Nascimento MM, Andrade CE, Silva RR, Queiroz-Telles F, de Hoog GS. Fonsecaea pugnacius, a Novel Agent of Disseminated Chromoblastomycosis. J Clin Microbiol. 2015 Aug;53(8):2674-85. PMC free article: PMC4508443 PubMed: 26085610
  97. Queiróz AJR, Pereira Domingos F, Antônio JR. Chromoblastomycosis: clinical experience and review of literature. Int J Dermatol. 2018 Nov;57(11):1351-1355. PubMed: 30113072
  98. Bhattacharjee R, Narang T, Chatterjee D. Cutaneous Chromoblastomycosis: A Prototypal Case. J Cutan Med Surg. 2019 Jan/Feb;23(1):98. PubMed: 30789034
  99. Huang X, Han K, Wang L, Peng X, Zeng K, Li L. Successful treatment of chromoblastomycosis using ALA-PDT in a patient with leukopenia. Photodiagnosis Photodyn Ther. 2019 Jun;26:13-14. PubMed: 30769166
  100. Rojas-García OC, García-Martínez JM, Carrión-Álvarez D. [Chromoblastomycosis in Mexico. A forgotten disease]. Salud Publica Mex. 2019 Ene-Feb;61(1):3. PubMed: 30753765
  101. He L, Ma J, Mei X, Lu S, Li X, Xi L. Successful treatment of chromoblastomycosis of 10-year duration due to Fonsecaea nubica. Mycoses. 2018 Apr;61(4):231-236. PubMed: 29178398

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *